Zydus Lifesciences arm to acquire U.S. oncology firm Assertio for $166 million

Zydus Lifesciences arm to acquire U.S. oncology firm Assertio for $166 million

Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock

Original Source

Read the full article at Thehindu →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.